US EUROPE AFRICA ASIA 中文
    China / Society

    China's first innovative drug approved NDA in the US

    By Shan Juan (chinadaily.com.cn) Updated: 2015-11-06 14:22

    The leading innovative pharmaceutical company with strong R&D capability and global vision in China market—Luye Pharma Group Ltd., announced that the United States Food and Drug Administration has confirmed that no additional clinical trials are needed for the New Drug Application (NDA) submission for Risperidone Extended-release Microspheres for Injection in the US.

    This will significantly cut down costs and time required for obtaining FDA approval for the drug. This is the first truly innovative drug manufactured in China that passes the audits of FDA and it is about to enter the NDA progress. This breakthrough marks Luye Pharma and China's first self-developed innovative drug will enter the US market in the near future.

    The drug is formulated as extended release microspheres for intramuscular injection for the treatment of schizophrenia and/or schizoaffective disorders. After the drug comes to the market, it is expected to improve medication compliance in patients with schizophrenia which is a common issue with oral antipsychotic drugs and would simplify treatment regimen since it needs to be injected only once every two weeks.

    Furthermore, it has advantages over another marketed drug, for example, there is no need to administer oral formulation during the three weeks after the first injection of the drug compared to the marketed drug. The stable plasma drug level can be reached much faster with it as compared to that marketed drug.

    On 10 September 2015, the Company had a meeting with the FDA on the drug. The FDA confirmed that the results of the completed pivotal study involving a total of 108 patients enrolled in the US can be used to support a NDA submission via the 505(b)(2) pathway for it without additional clinical trials. The Company is currently preparing the NDA report for the drug.

    According to World Health Organization, schizophrenia affects more than 21 million people worldwide, and one in two people living with schizophrenia does not receive treatment for the condition. It developed by Luye Pharma will bring gospel to a large number of patients living with schizophrenia. Luye believe it has good market potential and will enrich the Company's product pipeline. In addition to obtaining regulatory approval in the US, the Company is also targeting to obtain regulatory approval for it in Europe and Japan. Apart from this drug candidate, the Company is currently developing several new pharmaceutical products in the US, Europe and Japan.

    Highlights
    Hot Topics
    ...
    亚洲VA中文字幕无码一二三区| 免费无码av片在线观看| 久久无码国产专区精品| 中文无码字慕在线观看| 日韩AV无码久久一区二区| 亚洲国产精品狼友中文久久久| 久久久久久无码国产精品中文字幕 | 99高清中文字幕在线| 免费无码黄十八禁网站在线观看 | 中文字幕免费观看| 亚洲免费日韩无码系列| 国产精品va无码一区二区| 免费无码又爽又刺激网站直播| 国产一区二区中文字幕| 熟妇人妻中文a∨无码| 久久国产精品无码网站| 韩国免费a级作爱片无码| 亚洲av无码片在线播放| 最新中文字幕av无码专区 | 亚洲国产精品成人精品无码区在线| (愛妃視頻)国产无码中文字幕 | 久久久噜噜噜久久中文福利| 中文字幕无码久久久| 亚洲精品无码永久在线观看| 无码人妻少妇伦在线电影| 无码人妻丰满熟妇区五十路| 国产乱人伦Av在线无码| 无码内射中文字幕岛国片| 小13箩利洗澡无码视频网站| 无码人妻久久一区二区三区免费丨| 亚洲中文字幕无码久久综合网| 亚洲色无码一区二区三区| 亚洲国产精品无码久久一区二区| 亚洲一区二区三区无码中文字幕| 一本一道av中文字幕无码| 天堂а√在线中文在线最新版| 色噜噜综合亚洲av中文无码| 久久男人中文字幕资源站| 中文字幕1级在线| 亚洲日韩国产二区无码| 久久久久久亚洲AV无码专区|